Sandoz Talks US Biosimilars And Misinformation

Last month, in an opinion piece for the biologic therapies journal BioDrugs, Sandoz’ executive director for scientific affairs, Hillel Cohen, argued that the slow uptake of biosimilars in some markets may stem in part from patients and healthcare providers being subjected at times to “misleading, incomplete, out-of-context, and at times incorrect information about biosimilars.” (Also see "Misinformation Contributing To Slower Biosimilar Uptake, Execs Claim" - Generics Bulletin, 23 July, 2020.)